MX2021011943A - Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. - Google Patents

Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.

Info

Publication number
MX2021011943A
MX2021011943A MX2021011943A MX2021011943A MX2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A MX 2021011943 A MX2021011943 A MX 2021011943A
Authority
MX
Mexico
Prior art keywords
treatment
urothelial carcinoma
tyrosine kinase
kinase inhibitors
fgfr
Prior art date
Application number
MX2021011943A
Other languages
English (en)
Spanish (es)
Inventor
Porre Peter Marie Z De
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2021011943A publication Critical patent/MX2021011943A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
MX2021011943A 2019-03-29 2020-03-27 Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial. MX2021011943A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
US201962833395P 2019-04-12 2019-04-12
PCT/EP2020/058814 WO2020201138A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (1)

Publication Number Publication Date
MX2021011943A true MX2021011943A (es) 2021-11-03

Family

ID=69954076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011943A MX2021011943A (es) 2019-03-29 2020-03-27 Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.

Country Status (15)

Country Link
US (1) US20220175768A1 (cg-RX-API-DMAC7.html)
EP (2) EP3946340A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022527482A (cg-RX-API-DMAC7.html)
KR (1) KR20210143878A (cg-RX-API-DMAC7.html)
CN (1) CN113645975A (cg-RX-API-DMAC7.html)
AU (1) AU2020253054B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019203A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130773A1 (cg-RX-API-DMAC7.html)
IL (1) IL286727A (cg-RX-API-DMAC7.html)
JO (1) JOP20210260A1 (cg-RX-API-DMAC7.html)
MA (1) MA55486A (cg-RX-API-DMAC7.html)
MX (1) MX2021011943A (cg-RX-API-DMAC7.html)
PH (1) PH12021552352A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109854RA (cg-RX-API-DMAC7.html)
WO (1) WO2020201138A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021011926A (es) 2019-03-29 2021-11-03 Janssen Pharmaceutica Nv Inhibidores de fgfr tirosina cinasa para el tratamiento de carcinoma urotelial.
US20230321087A1 (en) * 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
WO2022243467A1 (en) * 2021-05-19 2022-11-24 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
AU2022289906A1 (en) * 2021-06-07 2023-11-09 R.P. Scherer Technologies, Llc Protective coating for moisture sensitive pharmaceutical compositions
IL312063A (en) 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
WO2023159216A1 (en) 2022-02-18 2023-08-24 Taris Biomedical Llc Erdafitinib formulations and osmotic systems for intravesical administration
CN116106240B (zh) * 2022-12-26 2025-11-07 华中农业大学 一种尿液酪氨酸检测体系、检测方法及检测试剂盒
IL322667A (en) 2023-02-13 2025-10-01 Taris Biomedical Llc Ardepitinib for intravesical administration for use in the treatment of bladder cancer
CN120731077A (zh) 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Also Published As

Publication number Publication date
EP4548935A3 (en) 2025-08-06
JP2026048748A (ja) 2026-03-17
MA55486A (fr) 2022-02-09
PH12021552352A1 (en) 2022-09-05
SG11202109854RA (en) 2021-10-28
EP3946340A1 (en) 2022-02-09
AU2020253054A1 (en) 2021-09-30
JP2022527482A (ja) 2022-06-02
CA3130773A1 (en) 2020-10-08
WO2020201138A1 (en) 2020-10-08
BR112021019203A2 (pt) 2021-11-30
KR20210143878A (ko) 2021-11-29
EP4548935A2 (en) 2025-05-07
CN113645975A (zh) 2021-11-12
AU2020253054B2 (en) 2026-01-08
JOP20210260A1 (ar) 2023-01-30
IL286727A (en) 2021-10-31
US20220175768A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
JOP20210260A1 (ar) مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية
MX2020011868A (es) Inhibidores de los receptores erbb.
EP4003993A4 (en) Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors
UY38837A (es) Proceso de elaboración de moduladores de cftr
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
MX2021005012A (es) Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr.
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
BR112017007769A2 (pt) compostos e composições para modulação de atividades de cinase de egfr mutante
EA201691916A1 (ru) Биарильные ингибиторы киназы
UY35798A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2017013797A (es) Inhibidor de janus quinasa.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
JOP20190233A1 (ar) نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
CL2019000573A1 (es) Composiciones para comprimidos.
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
MX2019010642A (es) Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
CU24707B1 (es) Inihibidores del factor d del complemento para administración oral
CO2024009144A2 (es) Inhibidores de cinasa met
AU2018284249A1 (en) Aminothiazole compounds as protein kinase inhibitors
BR112017022958A2 (pt) métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase
AR112217A1 (es) Una combinación de un inhibidor de mps1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta